The Benefits Of Spravato
In a historic vote, the FDA has approved Janssen Pharmaceuticals new medication, Spravato™, for clinical depression. This is the first time that Esketamine, a chemical cousin of Ketamine, has been approved for medicinal use. The 14-2 vote, with one abstained, provides new hope for people suffering from depression.
The last medication to be approved for depression was Prozac®, over 30 years ago. The problem in waiting so many years to approve new medication is that some cases of depression are resistant to certain medications.
Spravato must be administered by either a doctor or under supervision, and only after someone has tried other depression medications. This is due to its potency and potential hazards.
The Spravato labeling contains a Boxed Warning that cautions that patients are at risk for sedation and difficulty with attention, judgment and thinking (dissociation), abuse and misuse, and suicidal thoughts and behaviors after administration of the drug.
Spravato is only meant for people who have had no success with prior medications. This is due to the nature of its primary component, Esketamine. Esketamine gets its name from being chemically similar to Ketamine, a potent Hallucinogen and “club drug.” Ketamine was first created as an anesthetic for animals but was soon discovered to cause hallucinations when taken in large doses. This is what propelled its use as a club drug. For this reason, Spravato will not be available over-the-counter and can only be administered under supervision.
While the FDA has approved it, keep in mind that there have been 6 reported deaths of people using Spravato, 3 of which were suicides. An investigation has ruled that the medication was not responsible for these deaths. Still, it shows that this is not a miracle cure and should only be taken under supervision and at the discretion of a medical professional.
Break free from addiction.
You have options. Talk about them with a treatment provider today.
The Risk Of Spravato
Because of the risk of Spravato, patients who are given the medication must be monitored for at least 2 hours after taking it. It could be dangerous to drive or even walk home after the spray has been administered. If you or someone you love suffer from clinical depression, and other medications have failed in the past, talk with a doctor about Spravato. Do not, however, use it irresponsibly. It is a potent drug that could become hazardous when used incorrectly.
Cooper Smith earned his Bachelor’s in Writing for Entertainment from Full Sail University. While he was initially interested in a career in television, he saw an issue in his community and felt compelled to do something more. Now, he uses his knowledge to reach out to people who may need help and make the public aware of issues we are facing as a society. When he isn’t behind a computer, Cooper travels somewhere new.
- More from Cooper Smith
- Collier, Jasmin. (2019). The FDA approve esketamine nasal spray for severe depression. Retrieved on May 1, 2019 from https://www.medicalnewstoday.com/articles/324656.php
- Goldschmidt, Debra. (2019). FDA Approves Ketamine-Like Nasal Spray For Depression. Retrieved on March 6th, 2019, from https://www.cnn.com/2019/03/05/health/esketamine-depression-nasal-spray-fda-bn/index.html
- Janssen Pharmacsuticals. (2019). Janssen Announces U.S. FDA Approval of SPRAVATO™ (esketamine) CIII Nasal Spray for Adults with Treatment-Resistant Depression (TRD) Who Have Cycled Through Multiple Treatments Without Relief. Retrieved on March 6th, 2019, from https://www.janssen.com/janssen-announces-us-fda-approval-spravato-esketamine-ciii-nasal-spray-adults-treatment-resistant